Summary

Eligibility
for people ages 13-25 (full criteria)
Location
at UCSD
Dates
study started
estimated completion
Principal Investigator
Hari Narayan, MD (ucsd)

Description

Summary

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Official Title

Cancer Therapy Effects on the Heart: Identification of Early Markers of Cardiac Disease Progression After Cardiotoxic Childhood Cancer Therapy Using Cardiac Magnetic Resonance Imaging

Details

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Cardiac shape, function, and tissue characteristics will be examined using cardiac MRI data in combination with standard cardiac assessments (by echocardiography, electrocardiograms, and cardiac MRI) to assess the cardiotoxic effects of cancer therapy. Analyses will be performed in a cross-sectional cohort of adolescents and young adults with a history of childhood cancer.

Keywords

Cardiotoxicity Pediatric Cancer Heart Failure Cardiac magnetic resonance imaging (MRI) Echocardiography Electrocardiogram

Eligibility

You can join if…

Open to people ages 13-25

  • English and Spanish speaking male and female subjects, ages 14-25 years old
  • Previously treated for cancer, with diagnosis at least two years prior.
  • Patients whose cancer has recurred, persisted, is still detectable, or have developed a secondary cancer will still be eligible.

You CAN'T join if...

  • Patients who have a contraindication to contrast cardiac MRI, including the presence of non-MRI compatible metallic implants and severe renal dysfunction.
  • Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
  • Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
  • Patients with orthodontic braces or metallic implants in the thorax or abdomen/lumbar spine, even if MRI-compatible, will be excluded as these may cause artifacts and limit image quality.
  • Females who are pregnant.

Location

  • Rady Children's Hospital accepting new patients
    San Diego California 92123 United States

Lead Scientist at UC Cancer

  • Hari Narayan, MD (ucsd)
    Dr. Hari Narayan is a board-certified pediatric cardiologist at Rady Children's Hospital-San Diego and an assistant professor at UC San Diego School of Medicine. He specializes in cardiac imaging (echocardiography and cardiac magnetic resonance imaging). As a clinician and researcher, he seeks to improve the care of cancer patients receiving cardiotoxic therapies.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT04262830
Study Type
Observational
Last Updated